Source:http://linkedlifedata.com/resource/pubmed/id/12676256
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2003-4-4
|
pubmed:abstractText |
Type I plasminogen activator inhibitor (PAI-1) is a 50 kDa glycoprotein belonging to the serine protease superfamily. PAI-1 is consistently and dramatically upregulated in a variety of fibrotic diseases. The aim of this study was to compare PAI-1 expression in normal human buccal mucosa and oral submucous fibrosis (OSF) specimens and further explore the potential mechanism that may lead to induced PAI-1 expression. Twenty-five OSF specimens and six normal buccal mucosa were examined by immunohistochemistry. The activity of PAI-1 from cells cultured from OSF and normal buccal mucosa were assayed using reverse-transcriptase polymerase chain reaction (RT-PCR) and Western blots. PAI-1 expression was significantly higher in OSF specimens and expressed mainly by fibroblasts, endothelial cells, and inflammatory cells. In addition, OSF exhibited higher PAI-1 expression than normal buccal mucosa fibroblast (BMF) both in mRNA and protein levels. To verify whether arecoline, a major areca nut alkaloid, could affect PAI-1 expression by human BMFs, RT-PCR and Western blots were used. The results demonstrated highly elevated PAI-1 mRNA and protein expression in normal human BMFs stimulated by arecoline. Taken together, these results suggest that PAI-1 expression is significantly upregulated in OSF tissues from areca quid chewers, and arecoline may be responsible for the enhanced PAI-1 expression in vivo.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1368-8375
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2003 Elsevier Science Ltd.
|
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
367-72
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12676256-Areca,
pubmed-meshheading:12676256-Arecoline,
pubmed-meshheading:12676256-Blotting, Western,
pubmed-meshheading:12676256-Case-Control Studies,
pubmed-meshheading:12676256-Cells, Cultured,
pubmed-meshheading:12676256-Cheek,
pubmed-meshheading:12676256-Humans,
pubmed-meshheading:12676256-Male,
pubmed-meshheading:12676256-Mouth Mucosa,
pubmed-meshheading:12676256-Oral Submucous Fibrosis,
pubmed-meshheading:12676256-Parasympatholytics,
pubmed-meshheading:12676256-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:12676256-Precancerous Conditions,
pubmed-meshheading:12676256-RNA, Messenger,
pubmed-meshheading:12676256-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:12676256-Up-Regulation
|
pubmed:year |
2003
|
pubmed:articleTitle |
The upregulation of type I plasminogen activator inhibitor in oral submucous fibrosis.
|
pubmed:affiliation |
Institute of Biochemistry, Chung Shan Medical University, Taichung, Taiwan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|